[{"id":"9acf9d14-628b-4cc8-b958-9af380737382","acronym":"","url":"https://clinicaltrials.gov/study/NCT00087178","created_at":"2021-01-18T00:15:24.105Z","updated_at":"2024-07-02T16:36:05.609Z","phase":"Phase 3","brief_title":"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer","source_id_and_acronym":"NCT00087178","lead_sponsor":"NSABP Foundation Inc","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 amplification • TOP2A amplification","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • TOP2A amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • doxorubicin hydrochloride • cyclophosphamide • epirubicin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 2722","initiation":"Initiation: 05/01/2004","start_date":" 05/01/2004","primary_txt":" Primary completion: 03/01/2014","primary_completion_date":" 03/01/2014","study_txt":" Completion: 05/01/2016","study_completion_date":" 05/01/2016","last_update_posted":"2022-08-11"},{"id":"056223f5-9b84-49c2-a56b-ddafa97c5548","acronym":"","url":"https://clinicaltrials.gov/study/NCT00898898","created_at":"2021-01-18T03:27:15.701Z","updated_at":"2024-07-02T16:36:58.448Z","phase":"","brief_title":"Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831","source_id_and_acronym":"NCT00898898","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" HER-2 • MYC • PTEN • TOP2A","pipe":" | ","alterations":" HER-2 positive • MYC expression • TOP2A amplification","tags":["HER-2 • MYC • PTEN • TOP2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MYC expression • TOP2A amplification"],"overall_status":"Completed","enrollment":" Enrollment 2837","initiation":"Initiation: 05/01/2000","start_date":" 05/01/2000","primary_txt":" Primary completion: 01/01/2010","primary_completion_date":" 01/01/2010","study_txt":" Completion: 04/01/2019","study_completion_date":" 04/01/2019","last_update_posted":"2019-07-02"},{"id":"f412d8b7-c38d-4dfc-bd9c-450eede35f40","acronym":"","url":"https://clinicaltrials.gov/study/NCT00493649","created_at":"2021-01-18T01:45:57.099Z","updated_at":"2024-07-02T16:37:27.781Z","phase":"Phase 2","brief_title":"Adj TC + Herceptin Early Stage Breast Cancer","source_id_and_acronym":"NCT00493649","lead_sponsor":"US Oncology Research","biomarkers":" HER-2 • TOP2A","pipe":" | ","alterations":" TOP2A amplification","tags":["HER-2 • TOP2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TOP2A amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • cyclophosphamide • AP06 (trastuzumab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 493","initiation":"Initiation: 06/01/2007","start_date":" 06/01/2007","primary_txt":" Primary completion: 04/01/2013","primary_completion_date":" 04/01/2013","study_txt":" Completion: 04/01/2013","study_completion_date":" 04/01/2013","last_update_posted":"2016-11-03"}]